Acacetin, a Potent Transient Outward Current Blocker, May Be a Novel Therapeutic for <i>KCND3</i>-Encoded Kv4.3 Gain-of-Function-Associated J-Wave Syndromes.
Dan YeWei ZhouSamantha K HamrickDavid J TesterC S John KimHector Barajas-MartinezDan HuJohn R GiudicessiCharles AntzelevitchMichael J AckermanPublished in: Circulation. Genomic and precision medicine (2022)
This preclinical study provides pharmacological and functional evidence to suggest that Acacetin may be a novel therapeutic for patients with KCND3 gain-of-function-associated J wave syndrome by inhibiting I<sub>to</sub> and abolishing the accentuated action potential notch in patient-derived iPSC-CMs.